MOTS-C in District 2: Mitochondrial Stress Signaling and Exercise Adaptation Research
Research Snapshot
Research question: How might MOTS-c connect mitochondrial stress signaling with skeletal-muscle metabolism and exercise adaptation?
Scientific focus: Mitochondrial-derived peptides, AMPK signaling, metabolic stress responses, mitochondrial respiration, and exercise-associated changes in muscle.
Key development: A 2025 preclinical study reported that endurance training was associated with increased MOTS-c secretion and improved skeletal-muscle mitochondrial respiration through an AMPK/PGC-1α-related pathway. Earlier research found exercise-associated changes in endogenous MOTS-c in humans, while experiments involving administered MOTS-c and physical performance were primarily conducted in animal models.
Evidence status: Mechanistically interesting, with promising preclinical findings but insufficient human intervention evidence to establish MOTS-c supplementation as an effective exercise-adaptation strategy.
Primary sources: Free Radical Biology and Medicine (2025); Nature Communications (2021); Cell Metabolism (2015).
Key Takeaways
- MOTS-c is a mitochondrial-derived peptide: It is a 16-amino-acid peptide encoded by a short open reading frame within mitochondrial 12S ribosomal RNA.
- AMPK is a central mechanistic connection: Initial research linked MOTS-c to the folate–purine biosynthesis pathway and activation of AMP-activated protein kinase, a regulator of cellular energy balance.
- Exercise and MOTS-c are connected biologically: Human observations indicate that endogenous MOTS-c can change in response to acute exercise, but this does not establish that administering synthetic MOTS-c improves training outcomes.
- PGC-1α is relevant to mitochondrial adaptation: Research published in 2025 reported an association between endurance-training-induced MOTS-c signaling and the AMPK/PGC-1α pathway in skeletal muscle.
- Animal performance findings are not human efficacy data: Results from mouse experiments provide hypotheses for future research, not a validated performance-enhancement strategy.
- Human safety remains an important gap: The FDA’s 2026 briefing document states that it did not identify human exposure data for drug products containing MOTS-c or MOTS-c acetate.
1. What Is MOTS-c?
MOTS-c stands for mitochondrial open reading frame of the 12S rRNA-c. It belongs to a group of signaling molecules known as mitochondrial-derived peptides, or MD peptides. Unlike conventional proteins encoded by nuclear DNA, MOTS-c originates from a short open reading frame within the mitochondrial genome.
Mitochondria are best known for supporting ATP production through oxidative phosphorylation. However, they also participate in cellular communication. Changes in nutrient availability, energy demand, redox balance, and other forms of cellular stress can influence signaling pathways that affect metabolism and gene expression. Mitochondrial-derived peptides are being investigated as one possible component of this communication network.
The foundational MOTS-c study, published in Cell Metabolism in 2015, identified MOTS-c as a 16-amino-acid peptide associated with metabolic homeostasis. In experimental models, researchers reported effects involving skeletal-muscle metabolism, insulin sensitivity, and the AMPK pathway.
These findings helped establish MOTS-c as a research candidate in mitochondrial biology. They did not establish that an externally administered MOTS-c product improves exercise performance or provides a clinically meaningful benefit in humans.
2. Mitochondrial Stress Signaling: Why It Matters for Exercise
Exercise challenges the body’s energy-management systems. Contracting muscle requires increased ATP turnover, while changes in calcium signaling, cellular energy status, reactive oxygen species, and substrate availability help initiate adaptive responses.
These responses are not simply signs of cellular damage. Within appropriate physiological limits, exercise-related stress signals help the body adapt to repeated demands. Over time, this process can contribute to improved aerobic capacity, mitochondrial content, substrate utilization, and fatigue resistance.
MOTS-c is relevant to this field because experimental findings suggest that it may act as a signal connecting mitochondrial status with cellular metabolism. Researchers are investigating whether MOTS-c participates in the coordination of metabolic stress responses rather than acting as a direct source of energy or a substitute for exercise.
MOTS-c is being investigated for its potential role in regulating cellular responses to metabolic demand. That is different from supplying ATP directly, increasing oxygen delivery, or demonstrating that a product improves endurance. A plausible signaling mechanism is a starting point for research, not proof of a performance outcome.
3. The AMPK Connection: Cellular Energy Sensing
AMP-activated protein kinase (AMPK) is an important regulator of cellular energy balance. It responds to changes in cellular energy status and helps coordinate processes involved in energy production, nutrient utilization, and energy-consuming activity.
In the 2015 foundational study, researchers reported that MOTS-c inhibited aspects of the folate cycle and its connected de novo purine biosynthesis pathway. The resulting changes were associated with AMPK activation and altered metabolic regulation.
This proposed mechanism is relevant to exercise research because AMPK also responds to energetic demands during muscle contraction. However, the involvement of AMPK in both exercise and MOTS-c-related experiments does not prove that administering MOTS-c reproduces the full set of adaptations caused by training.
Exercise adaptation involves multiple overlapping systems, including calcium-dependent signaling, p38 MAPK, AMPK, transcriptional regulation, substrate availability, and changes in mitochondrial protein turnover. The importance of each pathway depends on factors such as exercise intensity, duration, training history, nutritional state, and the tissue being studied.
Consequently, AMPK activation should be interpreted as a mechanistic endpoint rather than a stand-alone measure of improved endurance, muscle recovery, or long-term health.
4. PGC-1α and Mitochondrial Adaptation
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) is a transcriptional coactivator involved in regulating genes associated with mitochondrial biogenesis, oxidative metabolism, and other adaptive processes.
Repeated exercise can stimulate pathways that influence PGC-1α activity and the expression of proteins involved in mitochondrial function. Over time, these responses can contribute to changes in the muscle’s oxidative capacity.
A 2025 paper in Free Radical Biology and Medicine, titled Endurance training enhances skeletal muscle mitochondrial respiration by promoting MOTS-c secretion, investigated the relationship between endurance training, MOTS-c, and mitochondrial respiration. The authors reported findings consistent with an exercise-associated MOTS-c response and involvement of the AMPK/PGC-1α pathway.
This research adds to the mechanistic case for studying MOTS-c in exercise adaptation. However, a pathway-related result does not independently establish that synthetic MOTS-c produces the same response as endogenous MOTS-c released during exercise. Nor does it establish the size, duration, or clinical significance of any effect in humans.
A Simplified Research Model
Exercise demand → changes in cellular energy and stress signals → candidate mitochondrial-derived signaling, including MOTS-c → AMPK-related signaling and potential PGC-1α involvement → changes in gene expression and mitochondrial function.
Important limitation: This is a simplified model of research hypotheses, not a proven linear pathway in which each step necessarily causes the next in every tissue or human participant.
5. What Do Human Exercise Studies Actually Show?
One important distinction in MOTS-c research is the difference between measuring a naturally occurring peptide during exercise and administering a synthetic version as an intervention.
A study published in Nature Communications in 2021 examined endogenous MOTS-c in human volunteers during an acute exercise challenge. In a small group of healthy, sedentary young men, researchers observed an increase in relative skeletal-muscle MOTS-c after exercise. Circulating MOTS-c also increased during and after the exercise bout and moved toward baseline during subsequent rest.
The same publication included experiments in cells and mice investigating physical performance, muscle metabolism, and responses to metabolic stress. The animal findings were promising, but the human exercise observations were not a randomized trial of administered MOTS-c.
This distinction matters for interpretation:
- Human biomarker observation: A naturally occurring peptide changes following exercise.
- Mechanistic experiment: Researchers investigate how a peptide affects cells or biological pathways.
- Animal intervention: Administered MOTS-c is evaluated in an animal model.
- Human clinical trial: An intervention is tested in people to determine efficacy, dose-related effects, and safety.
These forms of evidence answer different questions. The first three can justify further investigation, but they cannot replace controlled human trials of synthetic MOTS-c.
6. Evidence Table: MOTS-c and Exercise Adaptation
| Study or Evidence Source | Research Focus | Main Finding | Interpretation |
|---|---|---|---|
| Lee et al., 2015; Cell Metabolism | MOTS-c discovery and metabolic regulation | Reported effects involving the folate–purine pathway, AMPK, and metabolic homeostasis in experimental models. | Foundational mechanistic evidence, not a human exercise-performance trial. |
| Reynolds et al. and colleagues, 2021; Nature Communications | Exercise-associated MOTS-c and physical capacity | Reported exercise-related changes in endogenous MOTS-c in humans and performance-related findings in mice. | Supports biological relevance; does not establish efficacy of administered MOTS-c in humans. |
| MOTS-c exercise study, 2022; Physiological Reports | Physical activity, skeletal-muscle MOTS-c, and acute performance | Reported increased muscle MOTS-c expression after several weeks of voluntary running in rodents, alongside experiments examining acute exercise performance. | Preclinical evidence; species and study-design limitations remain. |
| Feng et al., 2025; Free Radical Biology and Medicine | Endurance training, MOTS-c secretion, and mitochondrial respiration | Reported a relationship between endurance training, MOTS-c, mitochondrial respiration, and AMPK/PGC-1α-related signaling. | Supports further pathway research; does not establish a clinically effective MOTS-c intervention in humans. |
| Mølmen et al., 2025; Sports Medicine | Human exercise training and mitochondrial adaptation | A systematic review and meta-regression synthesized evidence from 5,973 participants across 353 studies for mitochondrial outcomes. | Provides broader context for exercise-driven mitochondrial adaptation; it is not a MOTS-c treatment study. |
| FDA briefing document, 2026 | MOTS-c-related drug substances and compounding considerations | The FDA reported that it had not identified human exposure data for drug products containing MOTS-c or MOTS-c acetate and highlighted gaps in safety and characterization information. | Underscores that clinical safety and efficacy are not established. |
Sources: Cell Metabolism (2015); Nature Communications (2021); Physiological Reports (2022); Free Radical Biology and Medicine (2025); Sports Medicine (2025); FDA briefing document (2026).
7. Exercise Adaptation Is Broader Than Mitochondrial Respiration
Mitochondrial respiration is an important outcome, but it is only one part of exercise adaptation. A meaningful assessment of training effects may also examine:
- Aerobic capacity: Changes in measures such as maximal oxygen uptake (VO₂max) or exercise tolerance.
- Muscle oxidative capacity: The ability of skeletal muscle to use oxidative metabolism under defined conditions.
- Mitochondrial content and function: Measurements such as mitochondrial protein abundance, enzyme activity, or respiration under specified laboratory conditions.
- Metabolic flexibility: The ability to adjust substrate utilization according to physiological demand and nutrient availability.
- Muscle performance: Outcomes such as time-trial performance, fatigue resistance, or work capacity.
- Recovery and tolerability: Muscle function, delayed recovery, adverse events, and the ability to sustain training.
These outcomes are related but not interchangeable. A change in a signaling protein does not necessarily result in greater mitochondrial content, and an increase in mitochondrial respiration in an experimental preparation does not automatically translate into improved whole-body endurance.
For context, a 2025 systematic review and meta-regression of human exercise-training studies found that mitochondrial content increased across endurance, high-intensity interval, and sprint interval training categories. The review emphasized the importance of training load, frequency, and initial fitness level. These data demonstrate that exercise itself has a substantial evidence base for mitochondrial adaptation; they do not demonstrate that MOTS-c supplementation adds to that response.
A robust MOTS-c exercise study would distinguish molecular changes from functional results. Ideally, it would evaluate prespecified outcomes, include a suitable control group, monitor adverse events, and test whether any observed changes are meaningful to exercise capacity or training adaptation.
8. What Remains Unknown About Synthetic MOTS-c?
Despite increasing interest in mitochondrial-derived peptides, several major questions remain unanswered for externally administered MOTS-c.
Human efficacy
Available evidence does not establish that synthetic MOTS-c improves VO₂max, endurance, strength, training recovery, or other exercise outcomes in humans. Human observations of endogenous MOTS-c following exercise should not be interpreted as proof that an administered product reproduces the same biological response.
Dose–response relationships and pharmacology
Evidence is insufficient to establish an effective and safe human dose, the duration of relevant effects, or the relationship between exposure and response. The biological distribution and target tissues of administered MOTS-c also require further characterization.
Long-term safety
Short-term experiments in cells or animals cannot establish the safety of repeated or long-term exposure in humans. Potential immune responses, product-related impurities, aggregation, and other formulation-dependent risks require appropriate investigation.
Relationship to endogenous signaling
The amount, location, timing, and biological context of naturally produced MOTS-c may differ from exposure following administration of a synthetic peptide. It remains uncertain whether exogenous administration reproduces, amplifies, or alters the physiological signals associated with exercise.
9. Quality and Regulatory Considerations
The FDA’s 2026 briefing document on MOTS-c-related bulk drug substances identified important gaps in the available characterization, safety, and clinical evidence. The agency stated that it had not identified human exposure data for drug products containing MOTS-c or MOTS-c acetate. The briefing also discussed concerns involving peptide-related impurities, aggregation, and possible immunogenicity.
The document was prepared for an advisory-committee evaluation concerning potential inclusion on the U.S. 503A Bulk Drug Substances List. It should be read in that specific regulatory context rather than treated as a universal legal determination for every jurisdiction or research setting.
For peptide research, a certificate of analysis (CoA) should not be confused with proof of clinical efficacy or comprehensive product safety. A CoA’s value depends on the identity and quality of the material tested, the analytical methods used, the scope of testing, and whether the documentation can be linked to the specific batch. Purity alone does not establish sterility, endotoxin control, stability, correct formulation, or suitability for human administration.
Researchers evaluating peptide-related claims should distinguish chemical identity, analytical purity, batch-specific quality documentation, biological activity, and clinical evidence. These are separate questions requiring different types of evidence.
Official source: FDA briefing document on MOTS-c-related bulk drug substances (2026).
10. Statistics and Evidence at a Glance
| Metric | Reported Information | Why It Matters |
|---|---|---|
| Peptide length | 16 amino acids | Defines MOTS-c as a short mitochondrial-derived peptide. |
| Foundational publication | 2015 | Established the initial research framework for MOTS-c and metabolic homeostasis. |
| Human exercise observations | Small exploratory study in healthy young men | Supports investigation of endogenous MOTS-c responses but is not a clinical efficacy trial of synthetic MOTS-c. |
| Human exercise-training evidence | Systematic review included 5,973 participants across 353 studies for mitochondrial outcomes | Shows that training-induced mitochondrial adaptation has a broad evidence base independent of MOTS-c supplementation. |
| Human safety and efficacy of administered MOTS-c | Not established by the cited evidence | Prevents preclinical findings from being overstated as validated human benefits. |
Sources: Lee et al. (2015); Nature Communications (2021); Mølmen et al. (2025); FDA (2026).
11. Frequently Asked Questions
MOTS-c is a short peptide encoded by mitochondrial DNA and studied for its potential role in metabolic signaling. Research has linked it to pathways involved in cellular energy regulation, including AMPK-related signaling.
Studies have reported exercise-associated changes in endogenous MOTS-c and have investigated its potential relationship with mitochondrial function. These findings support further research but do not prove that synthetic MOTS-c improves training adaptations in humans.
The foundational 2015 study reported MOTS-c-related effects involving the folate–purine pathway and AMPK in experimental models. The extent to which these findings translate to human responses following administration remains uncertain.
PGC-1α helps regulate genes associated with mitochondrial adaptation. Research published in 2025 reported MOTS-c-related findings involving an AMPK/PGC-1α pathway in the context of endurance training. This does not establish that administering MOTS-c improves mitochondrial biogenesis or endurance in people.
The cited literature does not establish a clinically meaningful endurance benefit from administered MOTS-c in humans. Exercise-associated biomarker findings and performance results in animal models are not substitutes for controlled human intervention trials.
They may share the same intended peptide sequence, but their biological context and exposure can differ. Naturally produced MOTS-c is released and regulated within the body, while an administered product introduces a separate exposure whose pharmacology, quality, and safety must be established.
No FDA-approved drug containing MOTS-c is identified in the FDA’s 2026 briefing document. The available evidence does not establish it as an approved treatment for exercise performance, longevity, or metabolic disease.
A CoA may document selected analytical results for a particular material or batch. It does not, by itself, establish clinical efficacy, complete safety, sterility, endotoxin control, stability, or suitability for human administration.
Well-designed human studies would need to characterize exposure and safety, use suitable control groups, prespecify meaningful outcomes, and determine whether any molecular changes translate into measurable improvements in exercise capacity or other clinical endpoints.
There is no evidence establishing MOTS-c as a substitute for exercise training. Human research shows that structured exercise itself can increase mitochondrial content and improve aerobic fitness, while the additional clinical value of administering MOTS-c remains unestablished.
12. Related Articles and Research Resources
- Vietnam Peptides Knowledge Hub — Explore educational articles on peptide biology, metabolism, and current research.
- Peptide Research FAQ — Review general questions about peptide research, documentation, and product considerations.
- Research Peptide Products — Browse the site’s research-oriented product categories. Product listings should not be interpreted as evidence of clinical efficacy or regulatory approval.
13. Related Research Products
MOTS-C 20mg — Metabolic Research Peptide
This product listing is relevant to readers exploring MOTS-c as a research subject in mitochondrial-derived peptide signaling and metabolic regulation. The listing does not establish human efficacy, clinical safety, or suitability for administration.
SLU-PP-332 5mg — Exercise-Mimetic Research Compound
SLU-PP-332 is a separate investigational compound studied in relation to exercise-associated metabolic pathways. It is included here as an adjacent research topic, not as a mechanistic equivalent of MOTS-c or a clinically validated alternative to exercise.
Explore the Longevity Research Context
The personalized peptide plans page provides broader site context for longevity-related research topics. It should not be interpreted as a clinical recommendation to use investigational peptides.
14. Scientific References
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443–454. https://doi.org/10.1016/j.cmet.2015.02.009
- Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c is a regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12:470. https://doi.org/10.1038/s41467-020-20790-0
- MOTS-c increases in skeletal muscle following long-term physical activity and improves acute exercise performance after a single dose. Physiological Reports. 2022. Full-text article
- Feng Y, Rao Z, Tian X, et al. Endurance training enhances skeletal muscle mitochondrial respiration by promoting MOTS-c secretion. Free Radical Biology and Medicine. 2025;227:619–628. https://doi.org/10.1016/j.freeradbiomed.2024.12.038
- Mølmen KS, Almquist NW, Skattebo Ø. Effects of exercise training on mitochondrial and capillary growth in human skeletal muscle: a systematic review and meta-regression. Sports Medicine. 2025;55:115–144. https://doi.org/10.1007/s40279-024-02120-2
- U.S. Food and Drug Administration. FDA briefing document: MOTS-c-related bulk drug substances (MOTS-c free base and MOTS-c acetate). Pharmacy Compounding Advisory Committee meeting, July 23–24, 2026. Official FDA document
- U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Official FDA resource
Conclusion
MOTS-c provides a compelling research connection between mitochondrial-derived signaling, cellular energy regulation, and exercise adaptation. Foundational studies link the peptide to AMPK-related metabolic regulation, human observations show that endogenous MOTS-c can respond to exercise, and newer research continues to investigate its relationship with mitochondrial respiration and the AMPK/PGC-1α pathway.
The evidence nevertheless needs to be interpreted according to study design. Cell experiments, animal interventions, human biomarker observations, and controlled clinical trials cannot be treated as equivalent. Current findings do not establish that administered MOTS-c improves human endurance, recovery, or training adaptation, and the FDA’s 2026 briefing identifies substantial gaps in human exposure and safety information for MOTS-c-related drug products.
The most useful next step for the field is rigorous translational research: better characterization of MOTS-c biology, appropriately designed human safety studies, and controlled trials that connect molecular findings to meaningful functional outcomes. Until those data are available, MOTS-c is best understood as an investigational subject in mitochondrial and exercise biology—not a proven exercise-enhancement intervention.